Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 5/20 | 0.39 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.37 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.37 |
| ▸ | ESR1 | P03372 | 2/20 | 0.35 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.31 |
| ▸ | MAOA | P21397 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2497089 | 0.84 | MAOA (0.45) | PTGS2CYP19A1CYP11B2ESR1MAOA | |
| SCHEMBL2500803 | 0.77 | RXFP1 (0.40) | MAOAMEN1ALDH1A1MAPTKMT2A | |
| SCHEMBL2495862 | 0.77 | CYP19A1 (0.39) | PTGS2CYP19A1CYP11B2ESR1ESR2 | |
| SCHEMBL2498562 | 0.74 | RXFP1 (0.37) | MAOAMAPTKMT2A | |
| SCHEMBL2498560 | 0.74 | RXFP1 (0.37) | MAOAMAPTKMT2A | |
| SCHEMBL2500785 | 0.72 | MAOA (0.47) | PTGS2ESR1ESR2MAOAALDH1A1 | |
| SCHEMBL2500787 | 0.72 | MAOA (0.47) | PTGS2ESR1ESR2MAOAALDH1A1 | |
| SCHEMBL2498455 | 0.69 | RXFP1 (0.53) | MEN1ALDH1A1MAPTKMT2ANPSR1 | |
| SCHEMBL8192034 | 0.69 | PTGS2 (0.44) | PTGS2CYP19A1CYP11B2MEN1ALDH1A1 | |
| SCHEMBL21666686 | 0.69 | RXFP1 (0.46) | MAOAMEN1ALDH1A1MAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1817806-B1 | PHENOTHAZINES-S-OXIDES AND S,S-DIOXIDES AS hole and excitonblockers for OLEDs | BASF SE (DE) | 2014-07-30 | — | — | EP | disclosed |
| US-8029919-B2 | Phenothiazines, S-oxides, and S,S-dioxides as well as phenoxazines as emitters for OLEDs | BASF AKTIENGESELLSCHAFT (DE) | 2011-10-04 | — | — | US | disclosed |
| US-8029919-B2 | Phenothiazines, S-oxides, and S,S-dioxides as well as phenoxazines as emitters for OLEDs | BASF AKTIENGESELLSCHAFT (DE) | 2011-10-04 | — | — | US | disclosed |
| US-8029919-B2 | Phenothiazines, S-oxides, and S,S-dioxides as well as phenoxazines as emitters for OLEDs | BASF AKTIENGESELLSCHAFT (DE) | 2011-10-04 | — | — | US | disclosed |
| US-20100308714-A1 | Phenothiazines, S-Oxides, And S,S-Dioxides As Well As Phenoxazines As Emitters For Oleds | BASF AKTIENGESELLSCHAFT (DE) | 2010-12-09 | — | — | US | disclosed |
| US-20100308714-A1 | Phenothiazines, S-Oxides, And S,S-Dioxides As Well As Phenoxazines As Emitters For Oleds | BASF AKTIENGESELLSCHAFT (DE) | 2010-12-09 | — | — | US | disclosed |
| US-20100308714-A1 | Phenothiazines, S-Oxides, And S,S-Dioxides As Well As Phenoxazines As Emitters For Oleds | BASF AKTIENGESELLSCHAFT (DE) | 2010-12-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100308714-A1 | Phenothiazines, S-Oxides, And S,S-Dioxides As Well As Phenoxazines As Emitters For Oleds | PPOX, SMOX, SORD | PTGS2 221/4885CYP19A1 1476/4885CYP11B2 463/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.